Lipid-lowering study raises issues of therapy's value.

The article reports that pharmacists believe in the safety and efficacy of ezetimibe-simvastatin for hypercholesterolemia in the U.S. Preliminary results of the ENHANCE trial show no significant difference between the effects of simvastatin and ezetimibe-simvastatin, supporting the efficacy of the lipid-lowering therapy. Another clinical trial has been conducted to measure whether ezetimibe-statin is better than statin alone.